Baseline patient data from the TETON studies of Tyvaso ® Inhalation Solution in patients with idiopathic pulmonary fibrosis to be presented at ATS ATS presentation examines geographical barriers as a ...
Co announces the publication of two important studies: Long-term outcome in pulmonary arterial hypertension patients with subcutaneous treprostinil; and Rapid Switch from intravenous epoprostenol to ...
Research Triangle Park, NC and Silver Spring, MD United Therapeutics Corporation announced the FDA has issued an approvable letter for treprostinil sodium injection (Remodulin®) for the treatment of ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA ...
While we model declines in Remodulin and Adcirca, we expect Remodulin sales to be somewhat resilient to the impact of generics for a couple reasons. We believe that the sickest patients, who are often ...
A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a ...
United Therapeutics reported first-quarter results above our and FactSet consensus expectations. Its treprostinil franchise for pulmonary arterial hypertension (PAH) remains fairly stable despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results